Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy (NCT04637594)
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors. Immunotherapy with monoclonal antibodies, such as avelumab, durvalumab, pembrolizumab, atezolizumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stopping immune checkpoint inhibitors early may still make the tumor shrink and patients may have similar survival rates as the patients who continue treatment. Stopping treatment early may also lead to fewer treatment-related side effects, an improvement in mental health, and a lower cost burden to patients.
Who can join: Review the eligibility criteria below.
Location: Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (377 Sites)
Showing the first 25 of 377 sites.
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
- Alaska Women's Cancer Care — Anchorage, Alaska
- Anchorage Oncology Centre — Anchorage, Alaska
- Katmai Oncology Group — Anchorage, Alaska
- Providence Alaska Medical Center — Anchorage, Alaska
- Fairbanks Memorial Hospital — Fairbanks, Alaska
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Fresno Cancer Center — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
- Kaiser Permanente-Modesto — Modesto, California
- Kaiser Permanente Oakland-Broadway — Oakland, California
- Kaiser Permanente-Oakland — Oakland, California
- Stanford Cancer Institute Palo Alto — Palo Alto, California
- Kaiser Permanente-Rancho Cordova Cancer Center — Rancho Cordova, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Locally Advanced Bladder Urothelial Carcinoma
- ARID1A and/or KDM6A Mutation and CXCL13 Expression — Houston, Texas
- Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations — Los Angeles, California
- Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer — Birmingham, Alabama
- Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy — Los Angeles, California
- Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma — Atlanta, Georgia
Explore by condition: All Locally Advanced Bladder Urothelial Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.